Overview
This article addresses misconceptions about federal marijuana rescheduling and its implications for existing state marijuana systems. It argues that rescheduling to Schedule II will not threaten state-approved cannabis businesses or patient access, but will mainly impact research opportunities.
Legal Authority and Enforcement Discretion
- State marijuana businesses operate under Justice Department memos, not the Controlled Substances Act (CSA).
- The CSA explicitly outlaws marijuana enterprises, but DOJ enforcement discretion has deprioritized enforcement in compliant states.
- Rescheduling marijuana does not alter the authority or existence of DOJ memos permitting state-regulated operations.
- The FDA is unlikely to approve whole-flower marijuana products even after rescheduling, and FDA approval is not required for current state dispensaries to remain open.
Impact of Rescheduling on State Systems
- Shifting marijuana to Schedule II signals it is less dangerous, but does not legalize unapproved products or alter administrative deference to state laws.
- State-legal businesses will continue operating in a legal gray area, unaffected by rescheduling.
- The political optics make it unlikely for the government to tolerate marijuana as a Schedule I drug and then crack down after rescheduling.
Role of Presidential Prerogative
- DOJ memos, based on presidential enforcement discretion, are the basis for marijuana operations staying open.
- Rescheduling could further legitimize the memos by aligning marijuana's status with federal tolerance.
- Any reversal would require rescinding the memos, which is politically and practically unlikely.
- Both major presidential candidates at the time supported a hands-off approach toward state-legal systems.
Political and Logistical Barriers to Reversing Policy
- Shutting down state marijuana systems would be costly, difficult, and politically damaging.
- Failure to enforce stricter prohibition would be embarrassing for any administration, deterring attempts to reverse current policies.
Public Opinion
- Over 80% of Americans support medical marijuana, with majority support also for recreational use.
- Strong public support discourages federal attempts to close state dispensaries, as it would be politically unpopular.
Effects of Rescheduling on Legality and Research
- Rescheduling does not legalize state marijuana programs but reduces barriers for medical research on cannabis.
- It signals federal support for investigating the medical value of marijuana and eases access for researchers.
Differences Between State Markets and FDA-Approved Products
- State dispensary products differ significantly from those likely to be FDA-approved in the future.
- A dual system may emerge: FDA-approved cannabis drugs in pharmacies and other products in state dispensaries.
- Pharmaceutical companies are unlikely to seek FDA approval for most products currently sold in dispensaries.
Summary and Takeaways
- Rescheduling will not close dispensaries or disrupt patient access.
- The main impact will be fostering more research opportunities rather than changing day-to-day operations for most people.